Clinical Genomics Europe Conference interior header
 


Bio-IT World and Cambridge Healthtech Institute’s Second Annual

Genome Informatics
Deciphering Disease through Sequencing Data

5-6 December 2013 | Sheraton Lisbon Hotel & Spa | Lisbon, Portugal


Day 1 | Day 2 | Download Brochure | Biographies 

FRIDAY, 6 DECEMBER

08:00 Morning Coffee


THERAPEUTIC TARGETS 

08:30 Chairperson’s Opening Remarks

John Gurnett, Healthcare Field Director, EMEA, EMC

08:35 Clinical Genome Architecture Circuitry and Next-Generation Cancer Drug Targets

Dimitrios H. RoukosDimitrios H. Roukos, M.D., Ph.D., Founding Director, Centre for BioSystems & Genomic Network Medicine, CBS.GenNetMed and Department of Surgery, Ioannina University School of Medicine, Greece

The ENCODE data change the “central dogma” of one-gene/protein-one phenotype which continues to represent the foundation of all drugs developed and currently used in clinical practice. Latest advances in clinical genomics and dynamic signaling networks are presented revealing the exciting perspectives and challenges in targeting individual cancer patient and discovering the next-generation transcriptional circuitry-based drugs. Challenges and perspectives of genomic network medicine are discussed.

09:05 Big Data in Drug Discovery – Challenges and Perspectives

Philip GrothPhilip Groth, Ph.D., IT Business Partner, CoE Research, Bayer HealthCare Pharmaceuticals, Germany

After the discovery that mutations influence cancer initiation and development, targeted drugs like Crizotinib or Imatinib have shown dramatic effects on treatment of some cancers. To deepen understanding of the role of mutations in cancer, NGS has been employed to generate large-scale genomic mutation data. These “Big Data” must be stored, processed and analyzed to develop innovative cancer treatments. We present perspectives on cancer sequencing efforts, insights into the manifold technical, ethical, legal and scientific challenges and some solutions.

09:35 Using NGS and in vitro Models to Understand Structural and Regulatory Variation in Gastric Cancer

Carla OliveiraCarla Oliveira, Ph.D., Head, Expression Regulation, Cancer Group, IPATIMUP, Portugal

Gastric carcinoma (GC) is the second leading cause of cancer death worldwide with over 700,000 deaths per year. A systematic approach to identify subgroups of gastric cancer based on clinico-pathologic features, cancer-specific molecular profiles and patients’ survival is missing. We followed a strategy of gastric cancer stratification based on rigorous histo-pathology characterization and molecular profiling according to three important prognostic factors in gastric cancer (E-cadherin LOH, MSI and HER2). A collaborative team from IPATIMUP, Coimbra Genomics and BGI is currently performing WGRS, RRBS and RNA-seq of 50 pairs of stratified gastric cancers and paired normal tissue. Adequate bioinformatics pipelines and in vitro models, to validate candidate pathways emerging from our NGS approach, are in place at IPATIMUP. We hope to shed light onto GC-specific molecular signatures crucial for the identification of therapy targets and for the development of new therapeutic options.

10:05 Coffee Break in the Exhibit Hall with Poster Viewing


TRANSLATION INTO THE CLINIC 

10:45 The Ethical Introduction of Genome-Based Information and Technologies into Public Health

Heidi HowardHeidi Carmen Howard, Ph.D., Assistant Professor, Biomedical Ethics, IQ Healthcare, Radboud University Medical Centre, Netherlands and Senior Research Fellow, Département d’épidémiologie et de Santé Publique, INSERM, Faculté de Médecine, Université Toulouse, France

Public health genomics, wherein genomics would be integrated in all aspects of healthcare and public health, is gradually being proposed as a future reality. And, although laudable, these advances also bring with them a slew of ethical and social issues that challenge the normative frameworks used in clinical genetics until now. With this in mind, we highlight herein five principles that are used as a primer to discuss the ethical and responsible introduction of genome-based information and genome-based technologies into public health.

11:15 Challenges of Translation of Next-Generation Sequencing to Clinical Practice

Ángel CarracedoÁngel Carracedo, Ph.D., Director, Fundación Galega de Medicine Xenómica (FPGMX), Hospital Clínico Universitario, Spain

We will discuss some of challenges of the use of NGS for the diagnosis of Mendelian diseases and pharmacogenomics. Some of the main problems need advanced bioinformatics tools and are related to the amount of the data generated and the interpretation of variants of uncertain significance. We will show our approaches to face these problems.

IBM11:45 How the Electronic Healthcare Record Can Facilitate Translational and Integrative Medicine

Amnon ShaboAmnon Shabo, Ph.D., Project Leader, IBM Healthcare & Life Sciences Standards Program, IBM Haifa Research Lab

Health records could include various types of information generated along the translational continuum from discovery to policy and thus could facilitate the translational processes and enable meaningful reasoning by clinical decision support applications. To harmonize the various types of information, it is important to develop a universal health information language that is based on several languages/formats to represent data and knowledge. New effort in Clinical Genomics standardization will be presented.

 

KEYNOTE PRESENTATION 

12:15 pm The Ethical Dimensions of Data Sharing and the Maze of Identifiability

Anne Cambon-Thomsen, M.D.Anne Cambon-Thomsen, M.D., Director, Research, Centre National de la Recherche Scientifique (CNRS), France

The policies of data sharing are strongly re-affirmed by numerous research institutions and funders. This movement in the context of the availability of large-scale sequencing technologies for studying human genomic variation is confronted with the legal and ethical aspects regarding privacy, confidentiality, clinically useful information and the duties attached. Issues related to identifiability, consent process and regulation of access especially challenge the existing framework. Current developments will be discussed.

 

 

 

12:45 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

13:15 Session Break


RNA-Seq 

14:00 Chairperson’s Opening Remarks

Mary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Insitute (CHI), United States

14:05 Selected Poster Presentation: Identifying Fusion Genes in Cancer Samples

Liliana Greger, Ph.D., Research Scientist, Brazma Group, Functional Genomics, The European Bioinformatics Institute, EMBL

 

14:35 RNA-Seq and Microarray Gene Expression Vie for Superiority within a Comprehensive Study Design

Weida TongWeida Tong, Ph.D., Division Director, Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, FDA, United States

The 3rd phase of the FDA-led community-wide Microarray Quality Control (MAQC-III) project investigated the reliability and utility of RNA-Seq. All the samples in this project were profiled by both RNA-Seq and microarrays, which produced unprecedented opportunity to comprehensively compare RNA-seq with microarrays. RNA-Seq seems to provide comparable or better transcriptomic profiling as compared with the standard microarray technology for the elucidation of biological responses. This project involves ~200 participants from >80 organizations with comprehensive results that will impact FDA policy.

15:05 Multi-Platform and Cross-Methodological Reproducibility of Transcriptome Profiling by RNA-Seq in the ABRF Next-Generation Sequencing Study (ABRF-NGS)

Christopher MasonChristopher Mason, Ph.D., Assistant Professor, Computational Biomedicine, Weill Cornell Medical College, United States

We use standard reference samples to evaluate RNA-Seq across a range of sample quality levels, sample preparation methods and bioinformatics analysis approaches, with results that have the potential to improve the utility and comparability of these various methods and five NGS platforms (Illumina, PacBio, 454, PGM, Proton). Importantly, we demonstrate that even severely degraded RNA, when prepared and analyzed with appropriate methods, can be as useful as intact RNA for sequencing-based quantitative profiling.

15:35 Functional Dysregulation in Inflammatory Diseases

Carsten O. DaubCarsten O. Daub, Ph.D., Assistant Professor, Biosciences and Nutrition & Science for Life Laboratory, Karolinska Institutet, Sweden

Employing genome-wide expression profiling for contrasting disease and control patients allows not only identification of differentially regulated protein or non-coding transcripts but also inference of the underlying regulatory events.

 

16:05 Close of Conference



Day 1 | Day 2 | Download Brochure | Biographies 

*IBM and the IBM logo are trademarks of International Business Machines Corp., registered in many jurisdictions worldwide. 

 

Final Agenda 

Brochure Cover
Download Brochure
 

   

 Premier Sponsors 

 Aspera 

 

Dell_2011 


EMC
 


IBM 

Right Arrow View All Sponsors 

Right Arrow View Media Partners 

Sequencing

Clinical Exome Sequencing 

RNA-Sequencing 

Informatics

High-Scale Computing 

Genome Informatics 

Pre-Conference Symposia:

Clinical Epigenetics 

Digital Detection 


*IBM and the IBM logo are trademarks of International Business Machines Corp., registered in many jurisdictions worldwide.